This shift directly reflects DB-04 rapidly redirected scientific inquiry toward efficacy validation, mechanistic investigations, optimization strategies, and overcoming resistance mechanisms of targeted therapies (particularly ADCs).The 2023 joint update of HER2 testing guidelines by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) introduced substantive refinements in pathological interpretation and clinical management for HER2-low breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.